Table 1.
Demographic characterization of the study population (n = 14)
| N (%) | Mean (SD) | |
|---|---|---|
| Age, years | − | 73.9 (8.8) |
| Sex | ||
| Male | 11 (78.6) | − |
| Female | 3 (21.4) | − |
| CCI | − | 10.1 (1.6) |
| ECOG performance status | − | 0.8 (0.7) |
| Second-line therapy | 11 (78.6)a | − |
| Bisphosphonate therapy | 2 (14.3) | − |
CCI, Charlson Comorbidity Index.
All received gemcitabine/cis-platin as first-line therapy.